FDA proposes cutting off affordable GLP-1 access for millions
A move by the U.S. Food and Drug Administration could significantly change how millions of Americans access some of the most widely used weight loss medications on the market. On April 30, the FDA announced a proposal to remove glucagon-like peptide-1 (GLP-1) receptor agonists including semaglutide and tirzepatide, the active ingredients in Ozempic, Wegovy and […]